Literature DB >> 12569015

Effect of keratinocyte growth factor on the proliferation, clonogenic capacity and colony size of human epithelial tumour cells in vitro.

A Hille1, M Rave-Fränk, O Pradier, C Damm, W Dörr, M C Jäckel, H Christiansen, C F Hess, H Schmidberger.   

Abstract

PURPOSE: The effect of recombinant human keratinocyte growth factor (rHuKGF) on the proliferation, clonogenic capacity and colony size of low-passage human epithelial tumour cells was tested in vitro.
MATERIALS AND METHODS: Five tumour cell cultures derived from head and neck squamous cell carcinomas, three cultures derived from pleural effusions of carcinomas of different origin and normal human nasal epithelial cells were analysed in passages 2-4. Expression of FGF7 and its receptor (FGFR2) were determined by the RNase protection assay. Cells were incubated with rHuKGF (10-200 ng ml(-1)) 3 days before or immediately after plating for clonal growth in serum-depleted media. To determine cellular radiosensitivity, single doses of 1-8 Gy X-rays were applied. Colony formation as well as colony size, reflecting the number of cell divisions, was determined after 10-15 days of growth in rHuKGF-treated and control cells.
RESULTS: Normal nasal epithelial cells showed a two- to threefold increase in the number of cell divisions due to rHuKGF-treatment. In tumour cell cultures, significant stimulation of proliferation occurred in only one of eight samples. Tumour cells expressed FGF7 mRNA and protein, and low levels of FGFR2 mRNA. The addition of rHuKGF to the medium of the tumour cell cultures influenced neither radiation-induced impairment of proliferation nor clonogenic cell survival.
CONCLUSION: rHuKGF has been shown to ameliorate the radiation tolerance of normal epithelia. The minimum in vitro tumour cell response to rHuKGF compared with normal epithelial cells suggests a potential for selective protection of normal epithelia during radiotherapy. The low FGFR2 expression as well as the FGF7 expression in the tumour cells may contribute to their resistance to rHuKGF treatment.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12569015

Source DB:  PubMed          Journal:  Int J Radiat Biol        ISSN: 0955-3002            Impact factor:   2.694


  6 in total

1.  Bone marrow-derived mesenchymal stem cells in repair of the injured lung.

Authors:  Mauricio Rojas; Jianguo Xu; Charles R Woods; Ana L Mora; Willy Spears; Jesse Roman; Kenneth L Brigham
Journal:  Am J Respir Cell Mol Biol       Date:  2005-05-12       Impact factor: 6.914

2.  Effect of tumour-cell-derived or recombinant keratinocyte growth factor (KGF) on proliferation and radioresponse of human epithelial tumour cells (HNSCC) and normal keratinocytes in vitro.

Authors:  Andrea Hille; Susanne Grüger; Hans Christiansen; Hendrik A Wolff; Beate Volkmer; Jörg Lehmann; Wolfgang Dörr; Margret Rave-Fränk
Journal:  Radiat Environ Biophys       Date:  2010-03-07       Impact factor: 1.925

3.  Protective Effects of N-Acetylcysteine against Radiation-Induced Oral Mucositis In Vitro and In Vivo.

Authors:  Haeng Jun Kim; Sung Un Kang; Yun Sang Lee; Jeon Yeob Jang; Hami Kang; Chul-Ho Kim
Journal:  Cancer Res Treat       Date:  2020-06-18       Impact factor: 4.679

4.  Oral mucositis induced by anticancer treatments: physiopathology and treatments.

Authors:  D'Hondt Lionel; Lonchay Christophe; André Marc; Canon Jean-Luc
Journal:  Ther Clin Risk Manag       Date:  2006-06       Impact factor: 2.423

5.  Effect of epicatechin against radiation-induced oral mucositis: in vitro and in vivo study.

Authors:  Yoo Seob Shin; Hyang Ae Shin; Sung Un Kang; Jang Hee Kim; Young-Taek Oh; Keun Hyung Park; Chul-Ho Kim
Journal:  PLoS One       Date:  2013-07-18       Impact factor: 3.240

Review 6.  Palifermin for the protection and regeneration of epithelial tissues following injury: new findings in basic research and pre-clinical models.

Authors:  Paul W Finch; Lawrence J Mark Cross; Daniel F McAuley; Catherine L Farrell
Journal:  J Cell Mol Med       Date:  2013-09       Impact factor: 5.310

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.